Quantcast

Latest AbbVie Stories

2014-05-20 16:26:30

NORTH CHICAGO, Ill., May 20, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced today that the U.S. Food and Drug Administration (FDA) has granted HUMIRA(®) (adalimumab) orphan drug designation for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis, a group of rare but serious inflammatory diseases of the eye. AbbVie is investigating the efficacy and safety of HUMIRA for the treatment of non-infectious uveitis, and the clinical...

2014-05-20 08:32:20

NORTH CHICAGO, Ill., May 20, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 2014 UBS Global Healthcare Conference on Wednesday, May 21, 2014. Bill Chase, executive vice president and chief financial officer, will take part in a question and answer session at 9:30 a.m. Central time. A live audio webcast of the question and answer session will be accessible through AbbVie's Investor Relations Web site at www.abbvieinvestor.com. An archived edition of the session...

2014-05-16 23:09:18

The Long Island, New York law firm of Rudolph F. X. Migliore, P. C. has announced the Judicial Panel on MultiDistrict Litigation has scheduled a hearing session to consider consolidating lawsuits against AbbVie. Commack, New York (PRWEB) May 16, 2014 AbbVie, the makers of Androgel, allegedly made a defective medical product and hiding information about the defective drug Androgel, according to a number of federal lawsuits. The Judicial Panel on MultiDistrict Litigation has scheduled a...

2014-05-15 12:35:08

New Chief Scientific Officer Brings Wealth of Experience in Biotech and Key Therapeutic Areas NORTH CHICAGO, Ill., May 15, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) has named Michael Severino, M.D. its new Executive Vice President, Research and Development (R&D) and Chief Scientific Officer. Dr. Severino's track record of innovation within the biotech industry aligns with AbbVie's vision as a new biopharmaceutical leader with a rapidly emerging pipeline. Dr. Severino's...

2014-05-13 08:31:40

NORTH CHICAGO, Ill., May 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Merrill Lynch 2014 Health Care Conference on Thursday, May 15, 2014. Bill Chase, executive vice president and chief financial officer, will take part in a question and answer session at 10 a.m. Central time. A live audio webcast of the question and answer session will be accessible through AbbVie's Investor Relations Web site at www.abbvieinvestor.com. An archived edition...

2014-05-08 04:21:41

- Submission based on the largest Phase III program in genotype 1 (GT1) hepatitis C patients conducted to date1 NORTH CHICAGO, Ill., May 8, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) submitted marketing authorization applications (MAAs) to the European Medicines Agency (EMA) seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection. The MAAs are supported by...

2014-04-23 08:31:41

- Investigators to Present Clinical Trial Findings Evaluating Compounds in Multiple Tumor Types NORTH CHICAGO, Ill., April 23, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that data evaluating a number of investigational compounds in the company's oncology pipeline will be presented at the upcoming 50(th) Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30 - June 3, in Chicago. "Our clinical trial program underscores our commitment to developing innovative...

2014-04-22 08:34:00

-Submission based on the largest Phase III program in genotype 1 (GT1) hepatitis C patients conducted to date(1) NORTH CHICAGO, Ill., April 22, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection. The NDA is supported by...

2014-04-16 12:30:01

- Scholarship recognizes 40 exceptional students with cystic fibrosis (CF) who serve as role models for the community through academic excellence, creativity and community service NORTH CHICAGO, Ill., April 16, 2014 /PRNewswire/ -- AbbVie today announced that undergraduate and graduate students living with cystic fibrosis (CF) can now apply for the 2014 AbbVie CF Scholarship, which honors young adults with CF as they pursue higher education. Students can apply for the scholarship...

2014-04-15 08:29:16

Trial Will Evaluate Investigational Compound's Efficacy and Safety as an Addition to Standard Chemotherapy in Previously-Untreated Patients NORTH CHICAGO, Ill., April 15, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced the initiation of a global Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888), in patients with previously untreated locally advanced or metastatic squamous non-small cell lung cancer (NSCLC). The trial...


Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'